Month: February 2024

 PRESS RELEASEFebruary 16, 2024ROBUST 2023 RESULTS FOR MOBILIZE FINANCIAL SERVICESCAPITALIZING FROM A NORMALIZING AUTOMOTIVE MARKETMobilize Financial Services, the commercial brand of RCI Banque SA, posts strong growth in sales1 in 2023 as the automotive market returns to normal:The number of new financing contracts in 2023 will be 6.6% higher than in 2022. The amount of new financings will increase by 17.1% in 2023 compared with 2022, driven by a rise in registrations and average amounts financed (+9.9%) The penetration rate for electric vehicles stands at 48.1% in 2023, 5.2 points higher than the penetration rate for other types of engines The penetration rate stands at 43.4% (44.8% in 2022) The number of service and insurance contracts sold in 2023 will be 1.5% higher than in 2022.Mobilize Financial Services...

Aktia Bank Plc.Press Release16 February 2024 at 9 am. Aktia appoints Oscar Taimitarha as new Director in charge of Investor Relations Oscar Taimitarha, M.Sc. (Econ.), has been appointed Director of Investor Relations at Aktia. He will start in his position on 1 March 2024 and report to Outi Henriksson, CFO and member of the Executive Committee at Aktia. Oscar has worked at Aktia for the last 20 years and held several leadership positions, for example as Bank Manager and Regional Director. “I am delighted to see Oscar Taimitarha take over the position as Director of Investor Relations at Aktia. Oscar has a deep knowledge of Aktia’s business areas, especially banking, and has a wide network among our stakeholders. I am confident that he will bring Aktia’s dialogue with the investor community to the next level,” said Outi Henriksson. For...

Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globallyParis and Tarrytown, N.Y. February 16, 2024. The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. Japan is the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet needs. CSU is a chronic inflammatory...

Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally TARRYTOWN, N.Y. and PARIS, Feb. 16, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. Japan is the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet needs. CSU is a chronic inflammatory...